Table 3.
Associations between SMs and neurodegeneration biomarkers.
| NfL (pg/mL) | α-synuclein (pg/mL) | Neurogranin (pg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Metabolite | β | P | R2 | β | P | R2 | β | P | R2 |
| behenoyl SM (d18:1/22:0) | 0.06 | 1.23E-03 | 0.46 | 31.79 | 8.96E-04 | 0.09 | 46.86 | 0.08 | 0.04 |
| palmitoyl dihydro-SM (d18:0/16:0) | 0.15 | 2.14E-06 | 0.46 | 87.32 | 1.16E-07 | 0.11 | 148.66 | 0.01 | 0.05 |
| palmitoyl SM (d18:1/16:0) | 0.37 | 1.57E-18 | 0.52 | 254.75 | 1.72E-35 | 0.26 | 608.66 | 1.34E-15 | 0.10 |
| SM (d18:1/14:0, d16:1/16:0) | 0.16 | 8.83E-08 | 0.47 | 142.70 | 4.19E-18 | 0.16 | 336.80 | 1.74E-09 | 0.07 |
| SM (d18:1/18:1, d18:2/18:0) | 0.37 | 3.99E-17 | 0.51 | 247.38 | 3.30E-32 | 0.25 | 626.89 | 2.13E-15 | 0.10 |
| SM (d18:1/20:0, d16:1/22:0) | 0.17 | 2.34E-09 | 0.48 | 103.61 | 1.02E-12 | 0.12 | 207.71 | 8.00E-06 | 0.05 |
| SM (d18:1/20:1, d18:2/20:0) | 0.12 | 6.43E-05 | 0.45 | 64.18 | 3.29E-05 | 0.10 | 179.55 | 7.21E-04 | 0.05 |
| SM (d18:1/22:1, d18:2/22:0, d16:1/24:1) | 0.10 | 5.20E-06 | 0.46 | 50.48 | 1.34E-05 | 0.09 | 110.05 | 3.23E-03 | 0.05 |
| SM (d18:1/24:1, d18:2/24:0) | 0.09 | 1.30E-04 | 0.47 | 49.82 | 3.79E-05 | 0.09 | 81.38 | 0.04 | 0.04 |
| SM (d18:2/16:0, d18:1/16:1) | 0.22 | 5.16E-12 | 0.49 | 146.47 | 1.36E-19 | 0.17 | 337.93 | 1.39E-09 | 0.07 |
| SM (d18:2/24:1, d18:1/24:2) | 0.14 | 1.02E-08 | 0.48 | 75.29 | 2.36E-09 | 0.10 | 111.55 | 0.01 | 0.04 |
| stearoyl SM (d18:1/18:0) | 0.45 | 1.94E-21 | 0.53 | 325.23 | 1.25E-51 | 0.36 | 994.55 | 2.82E-28 | 0.18 |
SM: sphingomyelin; NfL: neurofilament light; β: change in the outcome with a one unit increase of the standardized metabolite level; P: P-value of the corresponding regression; R2: marginal R2 for the corresponding regression; bolded values indicate significant results at threshold p < 3.47×10−4.